BeOne Medicines (NASDAQ:ONC) COO Sells $106,400.00 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) COO Xiaobin Wu sold 280 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $380.00, for a total value of $106,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xiaobin Wu also recently made the following trade(s):

• On Tuesday, June 23rd, Xiaobin Wu sold 1,292 shares of BeOne Medicines stock. The stock was sold at an average price of $276.26, for a total value of $356,927.92.
• On Tuesday, June 16th, Xiaobin Wu sold 1,357 shares of BeOne Medicines stock. The shares were sold at an average price of $266.76, for a total value of $361,993.32.
• On Thursday, June 11th, Xiaobin Wu sold 626 shares of BeOne Medicines stock. The shares were sold at an average price of $261.20, for a total transaction of $163,511.20.
• On Monday, June 8th, Xiaobin Wu sold 1,484 shares of BeOne Medicines stock. The shares were sold at an average price of $269.37, for a total transaction of $399,745.08.

BeOne Medicines Price Performance

ONC opened at $366.73 on Friday. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17. The company’s 50-day moving average price is $325.53 and its 200 day moving average price is $311.31. BeOne Medicines Ltd. – Sponsored ADR has a fifty-two week low of $253.95 and a fifty-two week high of $385.22. The firm has a market cap of $40.26 billion, a price-to-earnings ratio of 64.57 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.65. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%.The firm had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.66 billion. As a group, sell-side analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 8.81 earnings per share for the current year.

Institutional Investors Weigh In On BeOne Medicines

A number of institutional investors have recently modified their holdings of ONC. Mariner LLC raised its stake in shares of BeOne Medicines by 3.8% in the fourth quarter. Mariner LLC now owns 883 shares of the company’s stock valued at $269,000 after acquiring an additional 32 shares during the last quarter. Farther Finance Advisors LLC grew its position in BeOne Medicines by 21.8% during the 4th quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock worth $66,000 after acquiring an additional 39 shares during the last quarter. CWM LLC increased its holdings in BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares in the last quarter. Steadtrust LLC increased its holdings in BeOne Medicines by 3.7% during the 2nd quarter. Steadtrust LLC now owns 1,400 shares of the company’s stock valued at $399,000 after purchasing an additional 50 shares in the last quarter. Finally, Benjamin Edwards Inc. raised its position in BeOne Medicines by 8.0% in the 4th quarter. Benjamin Edwards Inc. now owns 690 shares of the company’s stock valued at $210,000 after purchasing an additional 51 shares during the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ONC shares. Wolfe Research reissued an “outperform” rating and issued a $370.00 price target on shares of BeOne Medicines in a research note on Monday, August 10th. Zacks Research upgraded shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a report on Friday, August 7th. JPMorgan Chase & Co. upped their price target on shares of BeOne Medicines from $415.00 to $425.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Citigroup reaffirmed an “outperform” rating on shares of BeOne Medicines in a research note on Thursday, August 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $402.14.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.